Cost-Benefit Analysis of Expanding Bone-Marrow-Derived Mesenchymal Stem Cells (MSCs) Using Automated Cell Expansion Methods Versus Manual Methods
Live event: Tuesday, January 31, 2017 at 7:00 [PST] 10:00 [EST] 15:00 [GMT]
Evaluation of different options will be presented for scaling up large quantities of bone marrow-derived MSC (BMSC) using methods that can be performed in compliance with Good Manufacturing Practices (GMP).
This webinar is no longer available.
Do you have questions about this
webinar or wish to request related slides and materials? Please click
here to contact Terumo BCT and submit your request.
Evaluation of different options will be presented for scaling up large
quantities of bone marrow-derived MSCs (BMSCs) using methods that can be
performed in compliance with Good Manufacturing Practices (GMP). Topics
covered will include cell yields, cost, time, effort and ease of use
with either automated or manual methods to manufacture enough BMSC to
administer a single dose of 100 x 10^6 cells per patient.
What will you learn?
- Cost-benefit analysis for manual versus automated MSC manufacturing
for Phase I and II clinical trials
Who may this interest?
- Clinicians, researchers, lab technologists and cell
therapy industry professionals
- Cell therapy manufacturing professionals
Lead Medical Laboratory Scientist and Assistant Professor
Athena Russell is Lead Medical Laboratory Scientist of the Human
Cellular Therapy Laboratory and Assistant Professor of Laboratory
Medicine and Pathology at the Mayo Clinic in Jacksonville, Florida. Ms.
Russell is currently pursuing a Master’s degree in Biochemistry and
Molecular Biology at Mayo Graduate School. She has held multiple
positions at Mayo Clinic, concentrating her work on mesenchymal and
hematopoietic stem cell research, and other cellular and cell-derived
therapies. Athena also holds positions with the International Society
for Cellular Therapy and the American Association of Bioanalysts.
For a full list of other webinars available on RegMedNet please see here.